Drug-Induced Peripheral Neuropathy: Diagnosis and Management

dc.contributor.authorMerheb, Diala
dc.contributor.authorDib, Georgette
dc.contributor.authorZerdan, Maroun Bou
dc.contributor.authorEl Nakib, Clara
dc.contributor.authorAlame, Saada M.
dc.contributor.authorAssi, Hazem I.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:44:18Z
dc.date.available2025-01-24T11:44:18Z
dc.date.issued2022
dc.description.abstractPeripheral neuropathy comes in all shapes and forms and is a disorder which is found in the peripheral nervous system. It can have an acute or chronic onset depending on the multitude of pathophysiologic mechanisms involving different parts of nerve fibers. A systematic approach is highly beneficial when it comes to cost-effective diagnosis. More than 30 causes of peripheral neuropathy exist ranging from systemic and auto-immune diseases, vitamin deficiencies, viral infections, diabetes, etc. One of the major causes of peripheral neuropathy is drug-induced disease, which can be split into peripheral neuropathy caused by chemotherapy or by other medications. This review deals with the latest causes of drug-induced peripheral neuropathy, the population in-volved, the findings on physical examination and various workups needed and how to manage each case. © 2022 Bentham Science Publishers.
dc.identifier.doihttps://doi.org/10.2174/1568009621666210720142542
dc.identifier.eid2-s2.0-85125583483
dc.identifier.pmid34288840
dc.identifier.urihttp://hdl.handle.net/10938/30430
dc.language.isoen
dc.publisherBentham Science Publishers
dc.relation.ispartofCurrent Cancer Drug Targets
dc.sourceScopus
dc.subjectBrentuximab
dc.subjectChemotherapy-induced
dc.subjectDisulfiram
dc.subjectEpithelones
dc.subjectEribulin
dc.subjectNitrous oxide
dc.subjectPeripheral neuropathy
dc.subjectPlatinum drugs
dc.subjectProteasome inhibitors
dc.subjectSuramin
dc.subjectTaxanes
dc.subjectVinca alkaloids
dc.subjectAntineoplastic agents
dc.subjectHumans
dc.subjectPeripheral nervous system diseases
dc.subjectAntiinfective agent
dc.subjectBortezomib
dc.subjectBrentuximab vedotin
dc.subjectCarboplatin
dc.subjectCarfilzomib
dc.subjectChloroquine
dc.subjectCisplatin
dc.subjectColchicine
dc.subjectDapsone
dc.subjectDocetaxel
dc.subjectEpothilone derivative
dc.subjectEthambutol
dc.subjectGold salt
dc.subjectHydralazine
dc.subjectIsoniazid
dc.subjectIxabepilone
dc.subjectLeflunomide
dc.subjectLithium
dc.subjectMetronidazole
dc.subjectNitrofurantoin
dc.subjectOxaliplatin
dc.subjectPaclitaxel
dc.subjectPhenytoin
dc.subjectPlatinum
dc.subjectProteasome inhibitor
dc.subjectQuinoline derived antiinfective agent
dc.subjectQuinolone
dc.subjectSagopilone
dc.subjectStatin (protein)
dc.subjectTaxane derivative
dc.subjectTryptophan
dc.subjectTumor necrosis factor receptor superfamily member 8
dc.subjectVinblastine
dc.subjectVinca alkaloid
dc.subjectVincristine
dc.subjectAntineoplastic agent
dc.subjectAutoimmune disease
dc.subjectChemotherapy
dc.subjectCost effectiveness analysis
dc.subjectDiabetes mellitus
dc.subjectMicrotubule
dc.subjectNerve fiber
dc.subjectNonhuman
dc.subjectPathophysiology
dc.subjectPeripheral nervous system
dc.subjectPhysical examination
dc.subjectReview
dc.subjectVirus infection
dc.subjectVitamin deficiency
dc.subjectHuman
dc.titleDrug-Induced Peripheral Neuropathy: Diagnosis and Management
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-2135.pdf
Size:
1.76 MB
Format:
Adobe Portable Document Format